

Annual Report
Division of Rheumatology
Department of Medicine - Jewish General Hospital
January 1 - December 31, 2015

SUMMARY

Introduction:

Divisional members provide clinical services on Clinical Teaching Unit (CTU), out-patient clinic coverage, consult service as well as supervision of Internal Medicine residents and Rheumatology fellows as follows:

CTU: 2 weeks/year (Dr. Baron, Dr. Berkson and Dr. Fallavollita);

Consult service 3 months/year (Dr. Baron, Dr. Berkson, Dr. Fallavollita, Dr. Gyger);

Dr. Hudson: 1.5 months

Out-patient clinic (Dr. Baron 7 ½ days per week; Dr. Berkson 6 ½ days per week; Dr.

Fallavollita 6 ½ days per week; Dr. Gyger 7 ½ days per week)

Musculoskeletal ultrasound (Dr. Fallavollita 1 day)

Video capillaroscopy (Dr. Gyger ½ day)

In-Patient Follow up (Dr. Hudson 3 hours/day)

Supervision of 5 trainees for 2 half-days per week (Dr. Hudson 8 hours)

Staff members strive for clinical innovation. Dr. Baron has an ongoing scleroderma clinical, rheumatic disease/lung clinic.

1. Research and publications:

Dr. Baron's primary research interest is scleroderma. Dr. Baron has established the Canadian Scleroderma Research Group (CSRG) and the McGill Early Arthritis Registry that has performed research on recent onset inflammatory arthritis. He has also created CANCoRC, the Canadian Consortium of Rheumatology Cohorts, in an attempt to strengthen Canadian rheumatology research by seeking common funding and identifying commonalities across rheumatic disease research teams.

Most recently he established the International Systemic Sclerosis Inception Cohort (INSYNC) to study specifically recent onset cases of Scleroderma. This involves participation from many countries.

Dr. Baron's research has focused on ways of measuring disease activity and damage in scleroderma, as well as on aspects of nutritional deficiencies caused by the disease. In addition, he has brought in several labs to work with the biospecimens he has collected. They are working on multiple aspects of the disease, including the vascular abnormalities and control of fibroblast function.

He has also played an important role in Canada's rheumatic disease research community by creating the concept of the Systemic Autoimmune Rheumatic Diseases (SARDs) as a group that deserves attention as a whole rather than just individually.

Dr. Hudson pursues research in systemic autoimmune rheumatic diseases. In particular, she is a principal investigator in the Canadian Scleroderma Research Group (CSRG), a pan-Canadian cohort of over 1500 systemic sclerosis patients followed annually since 2004. She has done primarily outcomes research on this national dataset. In addition, given the rarity of the disease at hand, she has also established several international collaborations with leading scleroderma experts worldwide (International Scleroderma Renal Crisis Survey, Tri-nation (Canada, Houston, Australia) Scleroderma Cohort (undertaken to study the clinical correlates of some of the less frequent autoantibodies found in this disease), and International Systemic Sclerosis Inception Cohort (INSYNC).

Dr. Hudson is also the Director of the Canadian Inflammatory Myopathy Study (CIMS). Funded by a CFI grant awarded in 2010, we developed a study protocol to prospectively follow an incident cohort of patients with inflammatory myopathies. The database has been created, we have begun to recruit at 2 sites (McGill University and Centre Hospitalier de l'Université Laval). We aim to recruit approximately 100 incident cases per year over the next 3 years (2014-2017), making this a unique resource worldwide.

Finally, after doing outcomes research for several years, Dr. Hudson has now decided to also undertake translational research aimed at studying the etiopathogenesis of systemic autoimmune rheumatic diseases (SARDs). She has developed collaborations with a number of other scientists, including geneticists and environmental health experts, and has established the Canadian Network for SysTemic Autoimmune rheumatic diseases (CAN-STAR). The objective of this multi-disciplinary, cross-pillar, cross-disease network is to define the epigenetic signatures of SARDs, to investigate the contribution of air pollution to epigenetic abnormalities and to translate new findings into relevant disease biomarkers and targets for future intervention.

2. Teaching and learning (undergraduate and graduate):

The division continues to participate in undergraduate and post-graduate medical education. Its members provide clinical supervision to medical students, residents and fellows regularly during their 2-week as attendings on the medical wards, full-day weekly general rheumatology clinics and consult service. They participate in the CaRMS Admission Committee for Internal Medicine (3 hours/year).

Dr. Berkson has developed a Rheumatoid Arthritis versus Osteoarthritis lecture, a didactic and interactive lecture for first year medical students. Every two years since 2013, she has presented a seminar series on osteoporosis for rheumatology fellows. Dr. Berkson completed a course in Technology for Health Professions Education at Harvard Medical School in October 2015. This course has given Dr. Berkson digital/technological skills to develop and offer better rheumatology exposure for undergraduate and postgraduate medical students. In 2016 she was appointed chair of the Faculty of Medicine's Program Evaluation and Curriculum Outcomes Committee (Undergraduate).

Dr. M. Baron

2 weeks on medical ward

3 months on rheumatology consult service,

Frequently with students and residents in outpatient clinic

Co-supervision of rheumatology fellow with Dr. Hudson

Dr. L. Berkson

Osteoporosis Seminar x3 for Rheumatology Fellows (6 hours)
Lecture for Med1 x 1
Osler Fellow 4 hours/ month
12 weeks attending on consult service
½ day per week supervising residents in ambulatory care
2 weeks attending on 7W

Dr. S. Fallavollita

Working on developing US curriculum for students
Teaching undergraduate / postgraduate students and fellows

Dr. G. Gyger

Capillaroscopy course at the Rheumatology week-end
Capillaroscopy course to rheumatologists (around 25-30 hours per doctor)
RAC course (13 hours 45 min)
Small group rheumatology week-end (12 hours)
Staff that are training in capillaroscopy (25-30 hours per doctor)
Scleroderma introduction yearly (1 hour)
Scleroderma GI disease and capillaroscopy for pediatric fellows (45 min)

Dr. M. Hudson**Undergraduate teaching**

6 hrs "MSK Physical exam" 1st year medicine small group on introduction to MSK exam
2 hrs Approach to Arthritis Internal Medicine IIM lecture
2 hrs Approach to Gout and Septic Arthritis Clerkship
1 hr Clerks: Inflammatory Arthritis

Post Graduate Teaching

15 hrs McGill Simulation Center: Ethics (Internal Medicine R2 and 3)
Shoulder and Knee Injection and Aspiration (Internal Medicine R4)
3 hrs McGill Internal Medicine PGY4 Academic Half Day MSK exam
1 hr Family Medicine academic half day: Commonly encountered joint complaints
1 hr Internal Medicine PGY4 half day: Approach to Rheumatoid Arthritis
1 hr Academic half-Day: Rheumatology
1 hr Rheumatology Fellows: Approach to joint injections
72 hrs Internal Medicine TCP small group Teaching
10 hrs what is rheumatoid Arthritis
3 hrs/ week 2 residents
Supervision of Fellow Continuity Clinic
JGH Site Director Rheumatology Program
Supervision of trainees (undergraduate and postgraduate)

3. Involvement in the community:

Dr. M. Baron is President Scleroderma Clinical Trials Consortium.

Dr. M. Hudson is medical advisor to A WISH (Arthritis West Island Self-Help group).
Since 2011, she has served as Director of MS Quebec, and provides an introductory course in musculoskeletal exam and rheumatology for internal medicine residents from all 4 medical

schools in the province of Quebec. Each year, approximately 50 residents participate in this 2-day course in Orford, Quebec, which is funded by the Association des médecins du Québec.

Dr. Hudson spoke at the Cummings West Island Community Outreach, Arthritis on “A Growing Concern” and its impact on daily living.

4. Partnerships:

The rheumatology research group has instituted the development of a new international research organization called The International Systemic Sclerosis Inception Cohort (InSync) with the aim of closely following the first few years of illness in patients with scleroderma from many different countries to develop a large enough cohort for important research. InSync includes researchers from Canada, United States, Germany, Holland, Sweden, Australia and Spain.

Dr. Baron is President of scleroderma clinical trials consortium, a worldwide body of scleroderma researchers. He has established the Canadian Consortium of Rheumatology Research Cohorts (CANCoRC) which is a group of about 20 cohorts that work on cross-group efficiencies and look at biospecimen SOPs, biospecimen tracking systems, ethics submissions and consent forms, cross disease data harmonization, and sharing web page resources.

As described above, Dr. Hudson participates in research on epigenetics of rheumatic diseases with a group at McGill University (CAN_STAR) and has established a new national cohort in inflammatory myopathies (CIMS).

The Division runs an osteoporosis clinic in partnership with endocrinology. It has a once/month clinic for rheumatic disease with lung disease and/or pulmonary hypertension. Scleroderma patients are seen once per week for collection of data for the Canadian Scleroderma Research group.

5. Milestones:

There were no changes in staffing.

Dr. M. Hudson received FRSQ Chercheur-clinicien senior award (2015-2019) and was promoted to Associate Professor with tenure in the McGill Department of Medicine. She was appointed Director of Clinical Research at the Lady Davis Institute for Medical Research.

Dr. Berkson was appointed Chair of the Program Evaluation and Curriculum Outcome (PECO) Committee (Undergraduate Medical Curriculum, McGill University Faculty of Medicine).

6. Honours, awards, and prizes: None to report

Dr. Berkson was named Osler Fellow in McGill’s Faculty of Medicine. Dr. Hudson received the Jeffrey Shiroky Prize in recognition of contribution to inflammatory arthritis research, Laurentienne Conference, May 2016

7. Fundraising: None to report

SECTION I - DIVISION STATUS UPDATE

1. Mission and objectives of the Division

The Division strives to provide high level clinical care, education and research.

2. A nominative list of academic staff, their academic rank

Murray Baron, MD: Professor of Medicine
Marie Hudson, MD: Associate Professor with tenure
Genevieve Gyger, MD: Attending Physician
Laeora Berkson, MD: Associate Professor of Medicine
Sabrina Fallavollita, MD: Assistant Professor

SECTION II - GRANTS, PUBLICATIONS, AND SERVICE OUTSIDE OF McGill

1. Grants and awards received

Baron, Murray

Grouping of Canadian Companies and Corporations:

- A multicenter, open label study to describe the safety of daily subcutaneous injections of Anakinar (r-metHuIL-1ra) in patients with rheumatoid arthritis.
- Canadian Scleroderma Research Group.

JSS Medical Research

- A Canadian randomized controlled trial (RCT) of real world Cimzia treatment in RA: Randomizing to stop vs continued DMARDs.

Abbott Laboratories:

- Real life evaluation of rheumatoid arthritis in Canadians taking HUMIRA.

Hoffmann-La Roche Ltd, Canada :

- A Phase II/III, multicentre, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tocilizumab versus placebo in patients with systematic sclerosis.

Mount Sinai Hospital:

- The Canadian ArTHritis CoHort (CATCH): A prospective cohort study of adults with new-onset inflammatory arthritis symptoms.

Hudson, Marie

-Personal Support Awards

2015-2019	Chercheur-clinicien Senior	FRSQ	\$39,000/yr
2012-2015	Chercheur-clinicien Junior 2	FRSQ	\$35,000/yr
2012-2017	Investigator award	The Arthritis Society	declined

Roche: (PI)

- NT-proBNP to screen for SSe-PAH

Behring: (PI)
-Canadian Inflammatory Myopathy Study CSL

CIHR Co-PI
-Emerging Team: The Scleroderma Patient-centered Intervention Network (Emerging Team Grant: Rare Diseases)
-Multidimensional Epigenomics Mapping Centre (EMC) at McGill

Baxter PI:
Canadian Inflammatory Myopathy Study

Grouping of Canadian Companies and Corporations:
-The 1000 Canadian faces of lupus study.

Grifols Canada Ltd.:
-Canadian inflammatory myopathy study group.

JSS Medical Research:
-Prospective observational study to evaluate the use of musculoskeletal ultrasonography to improve rheumatoid arthritis management: Canadian experience (Echo Study).

Janssen Pharmaceutical Inc:
-Health-related quality of life (HRQoL) across systematic autoimmune rheumatic diseases (SARD)

CIORA PI:
-Preventing rheumatoid arthritis (Pre-RA): perspectives of people at risk and of rheumatologists on selected interventions

LDI PI:
-Epigenetic signatures of systemic autoimmune rheumatic diseases - A Pilot Study

Fallavollita, Sabrina

JSS Medical Research:
-Prospective observational study to evaluate the use of musculoskeletal ultrasonography to improve rheumatoid arthritis management: Canadian experience (Echo Study).

MUHC PI: Dr. Ines Colmegna:
-iT Profile and functional implications of the production of age- associated inflammatory cytokines by hematopoietic progenitor cells in RA

Abbott Laboratories Ltd:
Drug Canadian HUMIRA. Post Marketing Observational Epidemiological Study: Assessing Effectiveness in AS. Site contact and in charge of patient recruitment

Thombs, Brett

CIHR :

- Une intervention visant à réduire la détresse reliée à l'image corporelle chez les femmes avec défigurement causé par la sclérodémie
- Scleroderma patient-centered interventions network (SPIN).
- Assessing excess significance bias in randomized controlled trials of non-pharmacological interventions for pain management in rheumatic diseases.
- Understanding suicidal thinking and risk in a chronic, progressive disease: From epidemiology to application.
- Barriers to depression screening in medical setting: Examining cumulative false-positive rates and possible solutions in rheumatology, oncology, and cardiovascular care settings.
- Social anxiety from disfigurement due to medical illness: From assessment to intervention.
- Emerging Team: The Scleroderma patient-centered intervention Network.
- The Scleroderma patient-centered intervention network (SPIN) feasibility trial planning meeting.

McGill University

- William Dawson Scholar

Rare Disease Foundation:

- Testing the feasibility of the changing faces practitioner training and induction program for scleroderma patients.

Rheumatology Research Foundation:

- Health Professional Research Preceptorship

Natural Sciences and Engineering Research (NSERC):

- Social anxiety from disfigurement due to medical illness: From assessment to intervention.

Arthritis Society:

- The Scleroderma patient-centred intervention Network (SPIN).

Fonds de la recherche en santé du Québec (FRSQ) :

- La fatigue liée aux maladies chroniques dans la sclérodémie: de l'évaluation à l'intervention

Social Sciences and Humanities Research Council:

- Searching for identity in the dark: The experiences of women living in rare and unpredictable disease.

Grouping of Individuals:

- International Consortium for Behavioral/Educational/Psychological Interventions for Scleroderma. - SPIN COHORT NETWORK.

Research Foundation Sir Mortimer B. Davis, Jewish General Hospital:

- International Consortium for Behavioral/Educational/Psychological Interventions for Scleroderma. - SPIN COHORT NETWORK.

2. Research Trainees Supervised

Hudson, Marie

Undergraduate students

Julia Greenfield, Anatomy and Physiology, McGill University, BSc 2015

Julia was funded by the Canadian Scleroderma Research Group STIHR grant as a summer research trainee in the summer of 2013 to pursue a study comparing health-related quality of life across 4 systemic autoimmune rheumatic diseases. She had an abstract accepted for poster presentation at the 2014 Canadian Rheumatology Association Annual Scientific Meeting (February 2014, Whistler BC). A full-length manuscript of her work has been submitted.

Medical students

Stephanie Kelly, MCDM 2015 (McGill). Electrocardiographic abnormalities in systemic sclerosis

Teresa Semalulu, MDCM 2018 (Northern Ontario School of Medicine). Formulating evidence-based guidelines for the rational use of cardiac echocardiography to screen for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) (funded by Canadian Rheumatology Association-Roche Summer Studentship). Abstract accepted for an oral presentation at the 4th Systemic Sclerosis World Congress, Lisbon, Portugal, February 2016

Julie D'Aoust, MCDM 2015 (McGill), was initially funded by the Faculty of Medicine summer bursary program in the summer of 2012 and received an additional winter 2013 bursary to complete her project on Pm/Scl autoantibodies in SSc. She is first author on a manuscript that was published in *Arthritis and Rheumatology* (impact factor 7.5)

Charles Massie, MCDM 2016 (McGill), was funded by the Canadian Scleroderma Research Group STIHR grant. He completed a study looking at an association between anti-Ro antibodies and prolonged QTc in SSc. He is first author on a manuscript published in *Seminars in Arthritis Rheumatism* (impact factor 4.1).

Edward Zhang, MCDM 2015 (McGill), obtained a scholarship from The Arthritis Society and pursued a project on EKG abnormalities in SSc. He completed a systematic review and meta-analysis of the literature. He presented an abstract at the Canadian Rheumatology Association annual scientific meeting in February 2013 in Ottawa. A full-length manuscript is nearing completion.

2. Scholarly works published in the 2015 calendar year

--Bernatsky S, Smargiassi A, Barnabe C, Svenson LW, Brand A, Martin RV, **Hudson M**, Clarke AE, Fortin PR, van Donkelaar A, Edworthy S, Bélisle P, Joseph L. Fine; particulate air pollution and systemic autoimmune rheumatic disease in two Canadian provinces. *Environ Res*. 2016 Apr.; 146:85-91. doi: 10.1016/j.envres.2015.12.021. Epub 2015 Dec 24. PubMed PMID: 26724462.

--Jewett LR, Malcarne VL, Kwakkenbos L, Harcourt D, Rumsey N, Körner A, Steele RJ, **Hudson M**, **Baron M**, Haythornthwaite JA, Heinberg L, Wigley FM, Thombs BD; Canadian Scleroderma Research Group (CSRG); Canadian Scleroderma Research Group CSRG. Development and Validation of the Body Concealment Scale for Scleroderma (BCSS). *Arthritis Care Res (Hoboken)*. 2015 Dec 14. doi: 10.1002/acr.22819. [Epub ahead of print] PubMed PMID: 26663624.

--**Baron M**, Pope JE, Van Den Hoogen F, Khanna D, Fransen J, Johnson SR, Matucci-Cerinic M. Specificity of Systemic Sclerosis Classification Criteria. *J Rheumatol*. 2015 Dec;42(12):2512. doi: 10.3899/jrheum.150694. PubMed PMID: 26628709.

--Riehm KE, Kwakkenbos L, Carrier ME, Bartlett SJ, Malcarne VL, Mouthon L, Nielson WR, Poiraudau S, Nielsen K, **Baron M**, Frech T, **Hudson M**, Pope J, Sauve M, Suarez-Almazor ME, Wigley FM, Thombs BD; SPIN Investigators. Validation of the Self-Efficacy for Managing Chronic Disease (SEMCD) Scale: A Scleroderma - Patient-centered Intervention Network (SPIN) Cohort Study. *Arthritis Care Res (Hoboken)*. 2015 Nov 30. doi: 10.1002/acr.22807. [Epub ahead of print] PubMed PMID: 26619042.

--Levis B, Rice DB, Kwakkenbos L, Steele RJ, Hagedoorn M, **Hudson M**, **Baron M**, Thombs BD; Canadian Scleroderma Research Group. Using Marital Status and Continuous Marital Satisfaction Ratings to Predict Depressive Symptoms in Married and Unmarried Women with Systemic Sclerosis: A Canadian Scleroderma Research Group Study. *Arthritis Care Res (Hoboken)*. 2015 Nov 25. doi: 10.1002/acr.22802. [Epub ahead of print] PubMed PMID: 26605870.

--Pope JE, Rothfield NF, Ramsey-Goldman R, Smith CD, Bernatsky SR, Furie RA, **Hudson M**, Burgos-Vargas R, Senécal JL, Inanç M, van Vollenhoven RF, Chandran V, Nash PT, Muangchan C. Hydroxychloroquine treatment in SLE. *Arthritis Care Res (Hoboken)*. 2015 Nov 10. doi: 10.1002/acr.22777. [Epub ahead of print] PubMed PMID: 26555102.

--Oros Klein K, Grinek S, Bernatsky S, Bouchard L, Ciampi A, Colmegna I, Fortin JP, Gao L, Hivert MF, **Hudson M**, Kobor MS, Labbe A, MacIsaac JL, Meaney MJ, Morin AM, O'Donnell KJ, Pastinen T, Van Ijzendoorn MH, Voisin G, Greenwood CM. funtooNorm: an R package for normalization of DNA methylation data when there are multiple cell or tissue types. *Bioinformatics*. 2016 Feb 15;32(4):593-5. doi: 10.1093/bioinformatics/btv615. Epub 2015 Oct 24. PubMed PMID: 26500152; PubMed Central PMCID: PMC4743629.

--**Hudson M**. Scleroderma renal crisis. *Curr Opin Rheumatol*. 2015 Nov;27(6):549-54. doi: 10.1097/BOR.0000000000000221. PubMed PMID: 26352732.

--Wodkowski M, **Hudson M**, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Tatibouet S, Wang M; Canadian Scleroderma Research Group (CSRG); Australian Scleroderma Interest Group (ASIG); Genetics versus Environment in Scleroderma Outcome Study (GENISOS), **Baron M**, Fritzler MJ. Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. *Autoimmunity*. 2015;48(8):542-51. doi: 10.3109/08916934.2015.1077231. Epub 2015 Aug 31. PubMed PMID: 26334795.

--Wodkowski M, **Hudson M**, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Wang M, **Baron M**, Fritzler MJ; Canadian Scleroderma Research Group (CSRG); Australian Scleroderma Cohort Study (ASCS); Genetics versus Environment in Scleroderma Outcome Study (GENISOS). Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. *Clin Exp Rheumatol*. 2015 Jul-Aug;33(4 Suppl 91):S131-5. Epub 2015 Aug 27. PubMed PMID: 26315678.

--**Gyger G**, **Baron M**. Systemic Sclerosis: Gastrointestinal Disease and Its Management. *Rheum Dis Clin North Am*. 2015 Aug;41(3):459-73. doi: 10.1016/j.rdc.2015.04.007. Epub 2015 May 23. Review. PubMed PMID: 26210129.

--Kwakkenbos L, Minton O, Stone PC, Alexander S, **Baron M, Hudson M**, Thombs BD; Canadian Scleroderma Research Group. Can the Cancer-related Fatigue Case-definition Criteria Be Applied to Chronic Medical Illness? A Comparison between Breast Cancer and Systemic Sclerosis. *J Rheumatol*. 2015 Jul;42(7):1156-62. doi: 10.3899/jrheum.141421. Epub 2015 Jun 1. PubMed PMID: 26034154.

--Bernatsky S, Smargiassi A, Johnson M, Kaplan GG, Barnabe C, Svenson L, Brand A, Bertazzon S, **Hudson M**, Clarke AE, Fortin PR, Edworthy S, Bélisle P, Joseph L. Fine particulate air pollution, nitrogen dioxide, and systemic autoimmune rheumatic disease in Calgary, Alberta. *Environ Res*. 2015 Jul;140:474-8. doi: 10.1016/j.envres.2015.05.007. Epub 2015 May 16. PubMed PMID: 25988990; PubMed Central PMCID: PMC4492844.

--**Hudson M, Baron M**, Colmegna I, Bernatsky S, Klein Oros K, Pastinen T, Greenwood C. Novel approaches to discovery of biomarkers in rheumatoid arthritis: comment on the article by Oswald et al. *Arthritis Rheumatol*. 2015 May; 67(8):2276-7. doi: 10.1002/art.39189. PubMed PMID: 25988805.

--Dagenais M, MacDonald D, **Baron M, Hudson M**, Tatibouet S, Steele R, Gravel S, Mohit S, El Sayegh T, Pope J, Fontaine A, Masseto A, Matthews D, Sutton E, Thie N, Jones N, Copete M, Kolbinson D, Markland J, Nogueira-Filho G, Robinson D, Gornitsky M. The Canadian Systemic Sclerosis Oral Health Study IV: oral radiographic manifestations in systemic sclerosis compared with the general population. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2015 Aug; 120(2):104-11. doi: 10.1016/j.oooo.2015.03.002. Epub 2015 Mar 25. PubMed PMID: 25959972; PubMed Central PMCID: PMC4501825.

--Srivastava N, **Hudson M**, Tatibouet S, Wang M, **Baron M**, Fritzler MJ; Canadian Scleroderma Research Group (CSRG). Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect. *Semin Arthritis Rheum*. 2015 Oct;45(2):184-9. doi: 10.1016/j.semarthrit.2015.04.009. Epub 2015 Apr 10. PubMed PMID: 25959492.

--Muangchan C, van Vollenhoven RF, Bernatsky SR, Smith CD, **Hudson M**, Inanç M, Rothfield NF, Nash PT, Furie RA, Sénécal JL, Chandran V, Burgos-Vargas R, Ramsey-Goldman R, Pope JE. Treatment Algorithms in Systemic Lupus Erythematosus. *Arthritis Care Res (Hoboken)*. 2015 Sept; 67(9):1237-45. doi: 10.1002/acr.22589. PubMed PMID: 25777803.

--Liang L, Willis-Owen SA, Laprise C, Wong KC, Davies GA, Hudson TJ, Binia A, Hopkin JM, Yang IV, Grundberg E, Busche S, **Hudson M**, Rönnblom L, Pastinen TM, Schwartz DA, Lathrop GM, Moffatt MF, Cookson WO. An epigenome-wide association study of total serum immunoglobulin E concentration. *Nature*. 2015 Apr 30; 520(7549):670-4. doi: 10.1038/nature14125. Epub 2015 Feb 18. PubMed PMID: 25707804; PubMed Central PMCID: PMC4416961.

--Salazar GA, Assassi S, Wigley F, Hummers L, Varga J, Hinchcliff M, Khanna D, Schioppa E, Phillips K, Furst DE, Steen V, **Baron M, Hudson M**, Taillefer SS, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Molitor JA, Fritzler MJ, Segal BM, Al-Kassab F, Perry M, Yang J, Zamanian S, Reveille JD, Arnett FC, Pedroza C, Mayes MD. Antinuclear antibody-negative systemic sclerosis. *Semin Arthritis Rheum*. 2015

Jun;44(6):680-6. doi: 10.1016/j.semarthrit. 2014.11.006. Epub 2014 Nov 28. PubMed PMID: 25578738; PubMed Central PMCID: PMC4447614.

--**Baron M, Hudson M**, Tatibouet S, Steele R, Lo E, Gravel S, **Gyger G**, El Sayegh T, Pope J, Fontaine A, Masetto A, Matthews D, Sutton E, Thie N, Jones N, Copete M, Kolbinson D, Markland J, Nogueira G, Robinson D, Fritzler M, Gornitsky M. Relationship between disease characteristics and orofacial manifestations in systemic sclerosis: Canadian Systemic Sclerosis Oral Health Study III. Arthritis Care Res (Hoboken). 2015 May; 67(5):681-90. doi: 10.1002/acr.22490. PubMed PMID: 25303223; PubMed Central PMCID: PMC4464822.

3. Grant reviews

Hudson, Dr. Marie

-FRQS Comité d'évaluation des demandes de bourses chercheurs-cliniciens J2-Senior - 2016
-FRQS Comité d'évaluation FRQS, Comité 15 FF7-22P- 2015
-McGill Microbiome and Disease Tolerance Center (MDTC), 2015

SECTION III - CONFIDENTIAL INFORMATION

1. Consulting activities:

Name of Faculty Member	Private Sector Consulting (# of days)	Public Sector Consulting (# days)	Other (# of days – please explain)	Total
Fallavollita, S.	Abbott		2 days	2
Fallavollita, S.	Janssen		2 days	2
Fallavollita, S.	BMS		1 day	1
Fallavollita, S.	Roche		1 day	1
Fallavollita, S.	UCB		1 day	1

Submitted by:

Murray Baron, MD
Chief, Division of Rheumatology, JGH